2022
Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor
Jones DH, Bansal P, Bernstein JA, Fatteh S, Harper J, Hsu FI, O’Connor M, Park N, Suez D. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organization Journal 2022, 15: 100621. PMID: 35145604, PMCID: PMC8804245, DOI: 10.1016/j.waojou.2021.100621.Peer-Reviewed Original ResearchManagement of HAEMost patientsHereditary angioedemaC1 esterase inhibitorAngioedema attacksHAE attacksMedian ageClinical profileSerum levelsRhC1-INHTreatment outcomesRecombinant human C1 esterase inhibitorNormal C1 esterase inhibitorEsterase inhibitorHuman C1 esterase inhibitorAcute HAE attacksHigh-dose antihistaminesUS treatment centersPatient-reported assessmentsLow serum levelsPatient-reported outcomesC1-INH deficiencyAvailability of treatmentImproved disease controlBreakthrough attacks
2019
Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema
Valerieva A, Staevska M, Jesenak M, Hrubiskova K, Sobotkova M, Zachova R, Hakl R, Andrejevic S, Suiter T, Grivcheva-Panovska V, Karadza-Lapic L, Soteres D, Shapiro R, Rumbyrt J, Tachdjian R, Mehta V, Hsu FI, Zanichelli A. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema. The Journal Of Allergy And Clinical Immunology In Practice 2019, 8: 799-802. PMID: 31437566, DOI: 10.1016/j.jaip.2019.08.011.Peer-Reviewed Original ResearchConceptsRecombinant human C1 esterase inhibitorHuman C1 esterase inhibitorShort-term prophylaxisC1 esterase inhibitorHereditary angioedemaEsterase inhibitorProphylaxisAngioedemaPatients